Noncovalent Interactions of the Apple 4 Domain That Mediate Coagulation Factor XI Homodimerization*

Ryan DorfmanDagger and Peter N. WalshDagger §

From the Departments of Dagger  Biochemistry and § Medicine and the Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140

Received for publication, November 14, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Apple 4 (A4) domain of human plasma factor XI (FXI) was used to investigate the process of FXI noncovalent dimer formation. Recombinant 6-histidine-tagged A4 domain proteins were prepared utilizing a bacterial expression system. Purification was accomplished under denaturing conditions, followed by a refolding protocol to facilitate correct disulfide bond formation. Analysis of the A4 domain (C321S mutant) by size exclusion chromatography indicated the presence of a slowly equilibrating reversible monomer-dimer equilibrium. The elution profiles reveal highly symmetrical peaks for both dimeric and monomeric species with elution times that were highly reproducible for varying amounts of both the dimeric and monomeric species. The monomer-dimer equilibrium was found to be dependent upon changes in both pH and salt concentration. Under conditions approximating physiologic salt concentration and pH (20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4), it was determined that the monomer-dimer equilibrium was characterized by a dissociation constant (KD) value of 229 ± 26 nM with a calculated Delta G value of 9.1 kcal/mol. This report identifies electrostatic contributions and the presence of a hydrophobic component that mediate interactions at the A4 domain interface. The rate of dissociation for the recombinant A4 domain C321S mutant was examined by monitoring the increase in 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid dipotassium salt fluorescence under dissociating conditions, giving a value for a dissociation rate constant (koff) of 4.3 × 10-3 s-1.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human factor XI (FXI)1 is a plasma glycoprotein (~5% carbohydrate) involved in the intrinsic pathway of blood coagulation (1). FXI exists as a covalently linked two-chain homodimer, thus making it unique among coagulation factors. Dimeric FXI circulates in plasma as a zymogen in a 1:2 stoichiometric complex with the cofactor high molecular weight kininogen at plasma concentrations in the range of 4-6 µg/ml (~30 nM) (2, 3). Each subunit of the dimer contains 607 amino acids and has a molecular mass of ~80,000 Da based on reducing SDS gel electrophoresis (4). The activation of this zymogen to an active serine protease can be carried out in the presence of a polyanionic surface by activated factor XII and high molecular weight kininogen, thrombin, or activated FXI (FXIa) (4, 5). Activation is dependent upon cleavage of the peptide bond between Arg369 and Ile370 (6). Each subunit of FXIa is composed of a heavy (50,000 Da) and light (30,000 Da) chain held together via disulfide bonds (4). The light chain functions as a serine protease involved in the activation of coagulation FIX (7). The heavy chain of FXIa contains four tandem repeat sequences called Apple domains consisting of 90-91 amino acids each (8). Each of the four Apple domains contains three internal disulfide bonds, and the first and fourth Apple domains each contain one additional cysteine residue (9). Cys321 in the A4 domain has been implicated in the formation of a covalent FXI dimer (9). The first Apple domain (A1) contains distinct binding sites for cofactor high molecular weight kininogen, for thrombin, and for the Kringle 2 domain of prothrombin (10-12), whereas the second (A2) contains a FIX-binding site (13); the third (A3) has been implicated in interactions with platelets, with heparin, and with FIX (14-17); and the fourth (A4) contains an activated factor XII-binding site along with its ability to mediate dimer formation (9, 18, 19).

One of the more provocative questions surrounding FXI is its homodimeric structure and how that relates to its physiologic function in blood coagulation. FXI is activated on the platelet surface, and the resulting FXIa subsequently activates FIX (7). The recombinant A3 domain of FXI binds to the activated platelet surface with the same stoichiometry (~1500 sites/platelet) as that found for full-length dimeric FXI, suggesting that one A3 domain/dimer is responsible for the interaction with the platelet surface (16). Since it is difficult to rationalize one A3 (17) and/or A2 (13) domain of FXI binding to both FIX and to the platelet surface simultaneously, it has been hypothesized that the A3 domain from one subunit of the dimer binds the platelet, while the A2 and/or A3 domain of the opposite subunit interacts with FIX. Gailani et al. (20) recently demonstrated that recombinantly derived FXI monomers in which the A4 domain of FXI was replaced with that of prekallikrein (FXI/PKA4) in comparison with their dimeric counterparts (FXI/PKA4-Ala326 and wild-type FXI) were functionally defective in a partial thromboplastin time assay utilizing platelets as a surface, but normal with phospholipids. These results are consistent with the aforementioned hypothesis since the monomeric chimera bound to the platelet surface lacks an additional free A2 and/or A3 domain for interaction with FIX and would therefore be deficient in its ability to activate FIX. Additionally, FXI dimerization may be important for its ability to activate FIX since cleavage occurs at two spatially distinct sites. A detailed kinetic analysis of the activation of FIX by FXIa revealed that FIX is activated via a processive reaction mechanism without release of a singly cleaved intermediate (21). These findings suggest the possibility that each active site within the dimer carries out a single cleavage without the need for reorientation of the FIX molecule between successive cleavages, further suggesting that it may be functionally advantageous for FXI to exist as a dimeric molecule.

To fully understand the functional significance of FXI homodimer formation, we aim to define the structural determinants and mechanism involved in this process. Meijers et al. (19) demonstrated that at least part of the molecular information required for mediating dimer formation between the two identical subunits appears to reside within the A4 domain of FXI. Chimeric tissue plasminogen activator molecules with the A4 domain of FXI substituted for the finger and growth factor domains exist as dimers, as shown by gel filtration analysis (19). In the same chimeras as well as the full-length FXI protein, the replacement of Cys321 with serine results in molecules that also exist as dimers, as determined by gel filtration (19). These results strongly suggest that the A4 domains mediate noncovalent interactions resulting in dimer formation, which is subsequently stabilized by a covalent linkage between cysteine residues in each monomer at position 321 (9, 19). We have therefore prepared the rA4 domain of FXI as well as a C321S mutant to obviate covalent dimer formation and to permit determinations of binding constants under conditions of varying pH values and ionic strength. We employed a rapid gel filtration procedure similar to that described by Manning et al. (22) for the determination of natural and recombinant hemoglobin dissociation constants (KD).


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Pfu polymerase, DNA markers (lambda  DNA-HindIII digest, pBR322 DNA-MspI digest, and phi X174 DNA-HaeIII digest), restriction enzymes BamHI and PstI, and NEB buffer 2 were from New England Biolabs Inc. (Beverly, MA). All reagents used for SDS-PAGE were purchased from National Diagnostics, Inc. (Atlanta, GA). Ammonium persulfate and beta -mercaptoethanol were purchased from Bio-Rad. Bacto-Tryptone, Bacto-yeast extract, LB broth base (Lennox L broth base), T4 DNA ligase, dNTPs, and prestained protein molecular mass markers (low range) were from Life Technologies, Inc. DIAFLO® ultrafiltration membranes (3000-Da cutoff) and the Amicon 8200 stirred cell ultrafiltration apparatus were from Amicon, Inc. (Beverly, MA). Isopropyl-beta -D-thiogalactopyranoside (IPTG) was purchased from LabScientific, Inc. (Princeton, NJ). HEPES, CAPS, MES, Tris, cysteine, urea, guanidine, dithionitrobenzoate, and the MW-GF-70 gel filtration molecular mass marker kit were from Sigma. M15(pREP4) cells, the QIAexpress® pQE-9 vector, nickel-nitrilotriacetic acid (Ni2+-NTA) resin, the QIAEX II gel extraction kit, and the QIAquick polymerase chain reaction (PCR) purification kit were from QIAGEN Inc. (Chatsworth, CA). The Wizard® Plus miniprep DNA purification system was from Promega (Madison, WI). Bovine FXa was purchased from Hematologic Technologies, Inc. (Essex Junction, VT) or Enzyme Research Laboratories, Inc. (South Bend, IN). The enzymes lysozyme, trypsin, and endoproteinase Lys-C were from Calbiochem. HiTrap metal-chelating, Superose 12 (10 × 300 mm), and Superdex 75 (16 × 600 mm) columns were from Amersham Pharmacia Biotech. The Ultrafree®-15 centrifugal filter device, the Millex-GV 0.22-µm filter unit, and the Millex-HV 0.45-µm filter unit were from Millipore Corp. (Bedford, MA). The BCA protein assay reagent and the Slide-A-Lyzer® 3.5K dialysis cassettes were from Pierce. Sequenase Version 2.0 and reagents were supplied by United States Biochemical Corp. Spectrapor® dialysis membrane (9.3 ml/cm) was purchased from Spectrum Medical Industries, Inc. (Laguna Hills, CA). The chromogenic substrate S-2765 for measurement of FXa activity was purchased from Chromogenix (Mölndal, Sweden). The apolar probe 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid dipotassium salt (bis-ANS) was from Molecular Probes, Inc. (Eugene, OR).

Expression of Human FXI Apple 4 Domain and Mutants in Escherichia coli-- The rA4 domain construct contains sequences that code for Phe271-Glu361. The construct was generated by utilizing PCR and FXI cDNA as a template (a 2.1-kilobase pair EcoRI fragment containing the complete FXI coding sequence, a generous gift from Drs. Dominic W. Chung, Kazuo Fujikawa, and Earl W. Davie, Department of Biochemistry, University of Washington, Seattle, WA) to create a 318-base pair insert that is identical to that coding for the A4 domain of FXI.

Primers that flank either end of the A4 domain coding sequence were prepared by Life Technologies, Inc. The 5'-upstream primer contains an engineered BamHI restriction site (GGATCC) along with a FXa cut site (ATCGAAGGTAGA) that, when translated (Ile-Glu-Gly-Arg), was used to efficiently cleave an N-terminal 6-histidine tag. The 3'-downstream primer contains an engineered PstI restriction site (CTGCAG) along with a stop codon (TAA) to ensure transcription termination. The sequence of the upstream primer (5'-BamHI) is as follows: 5'-CGCGGATCC(ATCGAAGGTAGA)TTCTGCCATTCTTCATTTTAC. The sequence of the downstream primer (3'-PstI) is as follows: 5'-AAAACTGCAG(TTA)CTCATTATCCATTTTACACAA. The PCR was set up as follows: 10 ng of FXI cDNA as template, a 1 µM concentration of both the upstream (5'-BamHI) and downstream (3'-PstI) primers, 2.5 units of cloned Pfu DNA polymerase, 10 µl of 10× Pfu reaction buffer, and dNTPs at 0.2 mM brought to a final volume of 100 µl. The reaction mixture was then overlaid with 100 µl of mineral oil to prevent evaporation. The reaction mixtures were placed in a PerkinElmer Life Sciences DNA thermal cycler. The reactions were heated to 94 °C for 7 min, followed by 40 cycles at 94 °C for 1 min, 50 °C for 1 min, and 75 °C for 3 min. The reaction was completed by incubation at 75 °C for 7 min and a final incubation at 4 °C. The PCR was subsequently purified with the QIAquick PCR purification kit.

PCR was also performed in the generation of the C321S mutant (rA4-C321S). The PCR-based mutagenesis protocol was adapted from Picard et al. (23). Template plasmid DNA was obtained using a QIAGEN plasmid purification kit (~0.3-kilobase pair human FXI A4 domain subcloned into a pQE-9 expression vector). The mutagenesis reaction follows a three-step protocol. Step 1 involves synthesis of a megaprimer using a mutagenic primer and a downstream primer (3'-PstI). The mutagenic primer is as follows: 5'-CCAAGCATCC(A)GCAACGAAGG. The 11th base in the primer was switched from thymine in the wild-type sequence to adenine, thus allowing Cys321 to be replaced by serine in the mutant amino acid sequence. The reactions contained 10 ng of DNA template, 10 pmol (100 nM) each of the mutagenic and 3'-PstI primers, 2.5 units of cloned Pfu DNA polymerase, 10 µl of 10× Pfu reaction buffer, and dNTPs at 0.2 mM brought to a final volume of 95 µl. 10 cycles of amplification were performed for each step (94 °C for 1 min, 48 °C for 1 min, and 72 °C for 2 min). The reaction was completed by incubation at 75 °C for 5 min with a final incubation at 4 °C. Addition of 50 pmol of the upstream primer (5'-BamHI) to the aqueous phase begins step 2, and addition of 50 pmol of the downstream primer (3'-PstI) initiates step 3. The same amplification protocol as employed in step 1 is used in steps 2 and 3. The insert was cut with BamHI and PstI restriction enzymes using the protocols supplied by New England Biolabs Inc. The insert was ligated to the QIAexpress pQE-9 vector, and transformations were carried out using competent E. coli K12-derived M15(pREP4) cells. Expression from the pQE-9 vector was induced by the addition of IPTG.

Expression, Purification, and Folding of the rA4 Domain-- Large-scale expression cultures (1 liter) were propagated in LB broth in the presence of 100 µg/ml ampicillin and 50 µg/ml kanamycin at 37 °C. The large-scale cultures were inoculated from small-scale growth cultures (1:40, v/v). The cultures were grown until A600 reached 0.6-0.7. Induction of protein expression required the addition of 0.5 mM IPTG, followed by further incubation and shaking at 37 °C for 3 h. Cells were harvested by centrifugation (4000 × g for 20 min) and then stored as cell pellets at -70 °C. The concentration of protein was determined by absorbance at 280 nm employing an extinction coefficient of 12,420 M-1 cm-1 (per dimer). SDS-PAGE analysis was used to determine purity and to assure noncovalent association of subunits.

Harvested cell pellets stored at -70 °C were resuspended in Buffer A (6 M guanidine hydrochloride, 0.1 M NaH2PO4, and 0.01 M Tris-HCl, pH 8.0) at 5 ml of buffer/g of cells and allowed to stir at room temperature for 1 h. The supernatant was collected from the cell lysate following centrifugation at 10,000 × g for 15 min at 4 °C. The crude extract was then mixed with a Ni2+-NTA resin slurry (50% Ni2+-NTA and 50% Buffer A, 10-ml total volume). The mixture was then allowed to stir at room temperature for 1 h. The crude extract/resin mixture was loaded onto a 10-ml polypropylene column (QIAGEN Inc.). A series of wash steps then ensued: 5 column volumes of Buffer B (8 M urea, 0.1 M NaH2PO4, and 0.01 M Tris-HCl, pH 8.0), a wash with Buffer C (8 M urea, 0.1 M NaH2PO4, and 0.01 M Tris-HCl, pH 6.3) until the eluant absorbance at 280 nm was <0.01, and 20 ml of Buffer D (8 M urea, 0.1 M NaH2PO4, and 0.01 M Tris-HCl, pH 5.9). The FXI rA4 domain was then eluted with 20 ml of buffer E (8 M urea, 0.1 M NaH2PO4, and 0.01 M Tris-HCl, pH 4.5). Fractions containing protein were visualized by 15% SDS-PAGE.

The protein was then refolded using a protocol that makes use of a thiol/disulfide exchange in which cysteine is utilized as the low molecular mass reducing molecule (24). Protein concentration was held in the range of 200-250 µg/ml. A Spectrapor dialysis membrane (9.3 ml/cm) with a 3500-Da cutoff was used. The starting buffer consisted of 2 M urea, 20 mM Tris-HCl, 100 mM NaCl, and 2 mM cysteine at pH 9.0. A series of seven buffer changes was used to reduce the urea and cysteine concentrations (1 M urea and 1 mM cysteine; 0.5 M urea and 0.5 mM cysteine; 0.25 M urea and 250 µM cysteine; 0.1 M urea and 100 µM cysteine; and 0 urea and 0 cysteine). Upon completion of dialysis, the FXI rA4 domain was then concentrated via an Amicon stirred cell ultrafiltration apparatus using DIAFLO ultrafiltration membranes (3000-kDa cutoff). The protein solution was typically concentrated down to a volume of 2-4 ml, and the protein concentration (5.0 to 2.5 mg/ml) was determined. SDS-PAGE under reducing conditions was used throughout to monitor purification and under nonreducing conditions to detect correctly oxidized FXI rA4 domain.

The N-terminal 6-histidine tag was removed by cleavage with bovine FXa. Bovine FXa cleaves proteins at the C-terminal side of the recognition sequence Ile-Glu-Gly-Arg, which is identical to that engineered at the N terminus of the FXI rA4 domain. Cleavage buffer consisted of 20 mM Tris-HCl and 100 mM NaCl, pH 9.0. A 1:50 molar ratio of FXa to the FXI rA4 domain was used. The reaction mixture was incubated at 37 °C for 16-18 h. Upon completion of the reaction, success of cleavage was determined by SDS-PAGE analysis. Following the cleavage reaction, separation of the His-tagged FXI rA4 domain from the non-His-tagged FXI rA4 domain was carried out using the HiTrap metal-chelating column (5 ml). The HiTrap resin was charged with Ni2+ ions by applying 2.5 ml of a 0.1 M NiSO4 solution. The cleavage reaction was applied to the column, followed by a 5-column volume (25 ml) wash step (20 mM Tris-HCl and 100 mM NaCl at pH 9.0). The desired non-His-tagged FXI rA4 domain along with FXa was then eluted with 20 mM imidazole in the above buffer system.

The final step in the purification made use of gel filtration chromatography to separate the FXI rA4 domain from bovine FXa and to obtain protein that formed productive dimers. A Superdex 75 gel filtration column was equilibrated in 20 mM HEPES and 100 mM NaCl, pH 7.4. The proteins were resolved at a flow rate of 1 ml/min, and protein elution was monitored by absorbance at 280 nm. Fractions that eluted at a retention time representative of the dimeric FXI rA4 domain were pooled and concentrated with a Millipore concentrator. To determine the multimeric state of the eluted protein, data compiled for a standard curve were generated using the MW-GF-70 gel filtration molecular mass marker kit. To assess purity, all fractions were assayed for the presence of FXa using the chromogenic substrate S-2765. The protein was subsequently examined by SDS-PAGE.

The rA4 domain was examined by HPLC and matrix-assisted laser desorption ionization time-of-flight mass spectroscopy (analysis conducted by the Protein Chemistry Laboratory at the University of Pennsylvania, Philadelphia). The data demonstrated the presence of a single homogeneous species of protein with a molecular mass of 19,836 Da, which is consistent with the calculated molecular mass of the rA4 domain, which is 19,888 Da. Ellman's reagent (5,5'-dithiobis(2-nitrobenzoic acid)) was used to determine free sulfhydryl groups (25), which indicated <0.04 mol of free sulfhydryl group/mol of rA4 domain.

Size Exclusion Chromatography-- An Amersham Pharmacia Biotech fast protein liquid chromatography (FPLC) system was used along with an Amersham Pharmacia Biotech FPLC high resolution Superose 12 column (10 × 300 mm) to determine monomer-dimer KD for the FXI rA4 domain C321S mutant. A Superdex 75 column was also employed in purification and confirmation of dimer formation. To determine the multimeric state of the eluted proteins, data for a standard curve were compiled at varying pH values and salt concentrations using the MW-GF-70 gel filtration molecular mass marker kit. To construct standard curves, four proteins were employed with molecular masses as follows: albumin, 66,000 Da; carbonic anhydrase, 29,000 Da; cytochrome c, 12,400 Da; and aprotinin, 6500 Da. The effects of varying protein concentration, pH, and salt concentration were determined. All buffer solutions used to study pH effects contained 20 mM buffering reagent, 100 mM NaCl, and 1 mM EDTA. Buffering reagents for the various pH values tested were as follows: CAPS, pH 10.0; Tris-HCl, pH 9.0 and 8.0; HEPES, pH 7.0 and 7.4; and MES, pH 6.0. All buffer solutions used to study salt effects contained 20 mM HEPES, the appropriate NaCl concentration (0.025-2.0 M), and 1 mM EDTA, pH 7.4. For all experimental studies, the proteins were dialyzed against the appropriate buffer for 16-18 h in Slide-A-Lyzer dialysis cassettes. The resultant protein solution was cleared of any precipitate by centrifugation, and protein concentration was determined spectrophotometrically by absorbance at 280 nm with the previously stated extinction coefficient. Samples were then prepared by dilution of concentrated stock solutions and incubated for >= 3 h at room temperature to ensure that equilibrium was established. Samples of 100 µl at various protein concentrations were injected onto the pre-equilibrated column. Elution of resolved protein species was in the same buffer as the sample equilibration at a flow rate of 1 ml/min. The elution profile was followed by absorbance at 280 nm. The chromatograms were analyzed using FPLC Director software (Amersham Pharmacia Biotech). The retention times were determined by comparison of elution peaks at peak half-width and peak half-height. The calculated area under the elution peaks was used to determine the amount and percentage of dimeric and monomeric species present in the sample. A plot of the percent dimeric rA4-C321S as a function of the total protein concentration was used to determine dimer KD. All experimentally determined KD values (KD(app)) were divided by a dilution factor of 6.5 ± 0.27. The dilution factor was employed since dilution of the protein sample occurs as the protein is eluted through the column. The justification for this correction can be found under "Results" and in Refs. 22 and 36. The dilution factor equals the peak width at half-height (milliliter) divided by the sample load volume (100 µl) (22, 36).

Conversion of KD to the Change in Binding Energy (Delta G0)-- The Gibbs free energy of dissociation was calculated using the equation Delta G0 = -RT ln KD, where R is the gas constant (1.987 cal × mol-1 × K-1), T is the absolute temperature at which experiments were done (298 K), and KD is the dissociation constant or the concentration at which equal amounts of dimer and monomer exist in solution.

Fluorescence Spectroscopy-- Fluorescence measurements were performed on an SLM-AMINCO/Bowman Series 2 luminescence spectrometer. The stock solutions of bis-ANS were filtered, and the concentration was determined by absorbance at 385 nm using an extinction coefficient of epsilon 385 = 16,790 cm-1 M-1 (30). Varying amounts of the apolar probe were used to titrate the rA4 domain while monitoring extrinsic probe fluorescence. Protein concentrations were held constant at 0.5 µM. The samples were excited at 385 nm, and emission was monitored at 497 nm. The excitation and emission slit widths were set to 4 and 8 nm, respectively. All results were corrected with respect to spectra of buffer and protein background.

The establishment of dissociation kinetics was followed in a time-dependent manner by monitoring the increase in bis-ANS fluorescence as well. For dissociation kinetics, the protein was diluted to a concentration of 0.5 µM in the presence of 20 µM bis-ANS. The data were evaluated using the program KaleidagraphTM (Abelbeck Software) and fitted using a first-order equation with a single rate constant. The association rate constant (kon) for the conversion of monomer to dimer was calculated using the following equation, KD = koff/kon, where KD represents the dissociation constant determined by size exclusion chromatography and koff is the dissociation rate constant determined by fluorescence spectroscopy.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression and Purification of the rA4 Domain of FXI-- Since the FXI rA4 domain is expressed as insoluble inclusion bodies, its recovery requires solubilization, folding, and oxidation. To facilitate the purification of the rA4 domain, we generated an N-terminal 6-histidine-tagged fusion protein expressed in an E. coli K12-derived strain (M15(pREP4)). DNA corresponding to the A4 domain of FXI was PCR-amplified and placed in the pQE-9 expression vector. The vector contains a regulatable promoter/operator element allowing expression to be controlled by the addition of IPTG. Fig. 1A shows the expression of the rA4 domain compared with uninduced cells and cells induced with IPTG.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   SDS-PAGE analysis of FXI rA4 domain purification. A, small-scale expression cultures were analyzed by 15% SDS-PAGE for their ability to express the FXI rA4 domain. Cells were grown to mid-log phase (A600 ~ 0.6-0.7), induced with 0.5 mM IPTG, and incubated at 37 °C for an additional 3 h. Lane 1 represents a sample taken prior to the addition of IPTG, and lane 2 is representative of a sample induced with IPTG. Samples exposed to IPTG expressed the expected ~11-kDa protein, as shown by the appearance of a protein band not present in the "uninduced" sample. The uninduced sample (lane 1) demonstrates positive regulation of protein expression since no corresponding protein band was detected in the sample prior to the addition of IPTG. B, lane 1 represents the final protein product following gel filtration chromatography on a Superdex 75 column. The sample loaded in lane 1 was ~40 µg, indicating the high level of purity achieved.

Solubilization and purification took place in the presence of the denaturants 6 M guanidine hydrochloride and 8 M urea. We utilized the N-terminal 6-His tag as a molecular handle to facilitate binding of the recombinant protein by a high affinity interaction for the Ni2+-NTA resin (KD = 10-13 M at pH 8.0). Wash steps with subsequent stepwise decreases in pH allowed for the removal of contaminating proteins (Buffers B-D). The protein of interest was eluted at pH 4.5 (Buffer E), a condition favoring the protonation of the 6-His tag and thereby diminishing the interaction made with the Ni2+-NTA resin. The eluant was collected in 1-ml fractions and analyzed by both absorbance at 280 nm and SDS-PAGE. The FXI rA4 domain eluted in the first 10 ml of buffer E. This first step proved to be quite advantageous, allowing us to purify the fusion protein from the crude extract in one step with considerable purity. Purity was assessed by resolving the fractions by 15% SDS-PAGE and staining with Coomassie Blue (Fig. 1). The typical yield after the Ni2+ affinity chromatography step from a 500-ml culture was ~10 mg of denatured fusion protein.

The protein was then refolded using a protocol that makes use of a thiol/disulfide exchange in which cysteine is utilized as the low molecular mass reducing molecule (24). By stepwise removal of the urea, the protein slowly renatures, allowing the correct cysteine residues to come in close proximity of one another. Furthermore, the presence of cysteine molecules allows for a rapid disulfide exchange or reshuffling of incorrect disulfide bonds, which ultimately allows for formation of the most energetically favorable disulfide linkages. Even though the protein concentration during the folding step was held relatively low (200-250 µg/ml), a considerable amount of protein precipitate was observed at this step due to nonspecific aggregate formation. Approximately 30-50% of the protein was lost, making it the most inefficient step in the purification scheme. Protein folding, especially dependent upon disulfide bond formation, is highly sensitive to fluctuations in pH, temperature, and protein concentration (25, 26), which may account for the variability between preparations and the substantial loss of protein at this step. The protein that remained soluble was separated from the precipitate by centrifugation and ultrafiltration. Success of folding was examined by SDS-PAGE analysis under reducing and nonreducing conditions (Fig. 2) and gel filtration. Despite the considerable loss of protein at this step, protein that remained soluble was capable of forming productive dimers exclusively, as evidenced by distinct bands resolved by SDS-PAGE and single peaks on gel filtration chromatograms. Exclusive dimer formation at this step provides some evidence that protein folding was successful since improperly folded rA4 domains would conceivably produce a wide range of multimers. Mixed disulfide-bonded species tend to resolve as diffuse bands and multimeric ladders upon nonreducing SDS-PAGE as well as broad elution peaks upon gel filtration chromatography (25, 26). Total recovery of protein post-folding based on yields achieved from the initial Ni2+-NTA chromatography step were in the neighborhood of 50-70% or 5-7 mg.



View larger version (100K):
[in this window]
[in a new window]
 
Fig. 2.   SDS-PAGE of nonreduced and reduced samples of FXI rA4 and the rA4-C321S mutant. The rA4 domain migrated as a disulfide-linked dimer under nonreducing conditions and as a monomer under reducing conditions. The C321S mutant resolved as a monomer under both conditions, as expected. Lane M contains molecular mass markers.

The removal of the 6-His tag plus four amino-terminal residues (Met-Arg-Gly-Ser) was accomplished by cleavage with bovine FXa. Success of cleavage includes the removal of the 6-His tag plus the four amino acids (Ile-Glu-Gly-Arg) composing the FXa cut site. The molecular mass of the protein was reduced by 1854 Da to give a calculated molecular mass of 9943 Da/monomer. The cleavage reaction was monitored by SDS-PAGE analysis.

To separate the cleaved FXI rA4 domain (without the 6-His tag) from the noncleaved FXI rA4 domain, the digested sample was applied to a HiTrap metal-chelating column charged with Ni2+ ions. The digested sample contained primarily three species: bovine FXa, the 6-His-tagged A4 domain, and the non-6-His-tagged A4 domain. Following an initial wash step (20 mM Tris-HCl and 100 mM NaCl, pH 9.0), all three species remained on the column, which was somewhat unexpected since FXa and the nontagged A4 domain are devoid of histidine tags. However, both FXa and the A4 domain are capable of binding to a Mono QTM anion exchange column (data not shown) at pH 9.0, suggesting that these proteins are somewhat negatively charged at this pH. This may account for a nonspecific charge interaction with the positive Ni2+ ions bound to the column. Elution of the nontagged A4 domain was accomplished by addition of 20 mM imidazole to the buffer. Once again, 1-ml fractions were collected and assessed by absorbance at 280 nm and SDS-PAGE. Bovine FXa and the nontagged A4 domain coeluted in fractions 10-20 (10-20 ml). As a final step in the purification, the remaining protein was resolved on a Superdex 75 gel filtration column. The gel filtration step accomplished two goals: removal of bovine FXa (~45 kDa) and purification of only the A4 domain protein (~20 kDa) that is capable of forming productive dimers. Fractions that eluted at volumes corresponding to the dimer form of the FXI rA4 domain (~76 ml) were collected. Elution volumes were compared with a standard curve of log molecular mass versus elution volume generated by chromatography of the gel filtration molecular mass marker kit (data not shown). The collected fractions were also assayed with the chromogenic substrate S2765 to confirm separation of FXa from the A4 domain. Final purity was determined by SDS-PAGE analysis. It was conservatively estimated from the gel that the A4 domain was purified to >95% homogeneity (Fig. 1B). Based on the protein yield achieved after the Ni2+-NTA chromatography step, a final yield of ~1-2 mg (10-20% recovery) of pure FXI rA4 domain remained per 500 ml of expression culture.

Reducing and Nonreducing SDS-PAGE-- The SDS-PAGE results provided additional confirmation for both covalent (rA4) and noncovalent (rA4-C321S) dimer formation (Fig. 2). Size comparisons were made against low molecular mass markers (Life Technologies, Inc.). Samples of both rA4 and rA4-C321S beta -mercaptoethanol) were resolved by SDS-PAGE. Both reduced samples resolved corresponding to monomer molecular masses migrating between markers of 14 and 6 kDa (expected size of 9944 Da). The nonreduced rA4 domain resolved as a dimer migrating between molecular mass markers of 29 and 18 (expected size of 19,888 Da). The nonreduced rA4-C321S mutant resolved as a monomer identical to that of the reduced samples (Fig. 2). The results indicate that the wild-type rA4 domain exists as a dimer and that dimer formation is mediated by a disulfide linkage, as would be expected. The rA4-C321S mutant dimer does not contain a cysteine residue at position 321, but was still capable of forming dimers under native conditions, as seen from the gel filtration results (Fig. 3). Under nonreducing conditions, SDS was capable of disrupting the C321S dimer interaction, confirming that the mutant dimer interaction is mediated via noncovalent intersubunit amino acid interactions.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Representative dissociation curve and elution profile for rA4-C321S. Shown is a plot of percent dimer versus total rA4-C321S concentration (micromolar). 100% dimer represents a theoretical condition at infinite concentration of rA4-C321S. The conditions of the experiment include 20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4. An apparent dissociation constant (KD) of 1.49 µM (uncorrected for dilution of the sample on the column) was determined for the experimental conditions. The inset represents elution profiles of varying total protein concentrations (0.25, 0.5, 1.0, 2.0, and 10 µM) injected onto a pre-equilibrated Superose 12 column. The protein was diluted to the appropriate concentration in 20 mM HEPES, 100 mM NaCl, and 1 mM EDTA at pH 7.4 and incubated at room temperature (~25 °C) for >3 h to establish equilibrium. The elution profiles were followed by the absorbance at 280 nm, and the amounts of protein present as monomer and dimer were assessed by peak area determined by FPLC Director software. With a flow rate of 1 ml/min, the retention times are equivalent to elution volume in milliliters. The peak labeled Dimer refers to the elution of dimer, and that labeled Monomer refers to that of monomer.

Dimerization Assay-- A high resolution Superose 12 column (10 × 300 mm) was used to develop a dimerization assay to determine monomer-dimer KD for mutant rA4 domains of FXI. Similar assays have been described by both Manning et al. (22) and Gallagher and Huber (27) to measure tetramer-dimer dissociation constants of natural and recombinant hemoglobins and the monomer-dimer equilibrium of M15 beta -galactosidase from E. coli, respectively. To determine the multimeric state of the eluted protein, data for a standard curve were compiled under varying conditions using the MW-GF-70 gel filtration molecular mass marker kit (see "Experimental Procedures"). Peak area, determined by FPLC Director software, was used to calculate the percent dimeric and monomeric species for each sample. A plot of percent dimeric rA4-C321S as a function of the total rA4-C321S concentration prior to application to the column gave a hyperbolic curve. A representative dissociation curve for the C321S mutant along with elution profiles (chromatograms) are presented in Fig. 3. The elution volumes of the two peaks labeled dimer (14.4 ml) and monomer (16.7 ml) in Fig. 3 correspond to molecular masses of 21,060 and 8291 Da, respectively. These masses correspond well to the theoretical calculated monomer (9944 Da) and dimer (19,888 Da) forms of the protein. Under conditions approximating physiologic salt concentration and pH (20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4), it was determined that the monomer-dimer equilibrium was characterized by a KD(app) of 1.5 ± 0.2 µM. This value of KD(app) was corrected for a 6.5-fold dilution factor during the gel filtration procedure (22, 36) to give a KD value of 229 nM. The justification for this correction is given in the last paragraph under "Results" and in Refs. 22 and 36.

The results indicate that the monomer-dimer equilibrium of rA4-C321S is reversible, as evidenced by a shift in the ratio of dimer to monomer as a function of decreasing protein concentration. The reversibility of the equilibrium was also demonstrated by subjecting the dimer peak to a second round of chromatography and observing the presence of two peaks corresponding to dimer and monomer (data not shown). The equilibrium can be driven to completion, generating either nearly all dimeric or monomeric species, indicating that all the protein present in the reaction is functional and participates in the equilibrium process. The elution times were highly reproducible for both varying amounts of the dimeric and monomeric species, as evidenced by peak width at half-height determinations. All elution profiles resolved as highly symmetric peaks, indicative of a mixture of monomeric and dimeric rA4-C321S domains in slow equilibrium between species (28). The lack of peak broadening also rules out potentially nonspecific interactions with the column material.

These results indicate that the A4 domain by itself is sufficient to cause dimerization and that the interchain disulfide bond at C321S is not necessary for dimer formation. These findings are consistent with the results of Meijers et al. (19) for the Cys321 mutant of full-length FXI, which migrated as a dimeric molecule upon gel filtration. Conclusively, the analysis indicates that the C321S mutant exists in a reversible monomer-dimer equilibrium that can be measured and used to determine the KD(app) for this interaction under varying conditions.

A time course for dissociation using the same size exclusion chromatography method was examined (Fig. 4). A stock solution of the rA4-C321S domain (~25 µM) was diluted to 2.0, 0.75, and 0.35 µM in buffer containing 20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4. Aliquots were then resolved on a Superose 12 column at various times post-dilution. The data were subjected to linear regression analysis. We observed that the equilibrium was essentially stable over the time scale tested, demonstrating that equilibrium had already been achieved prior to our measurements. The final monomer concentration for all three trials (2.0, 0.75, and 0.35 µM) after equilibrium was established and was internally consistent with our experimentally determined KD(app) of 1.5 µM. A solution of rA4-C321S at concentrations of 2.0, 0.75, and 0.35 µM should be ~40, 65, and 80% monomeric, respectively. This is exactly what we observed. This observation leads us to conclude that all the protein participates in the equilibrium process. However, this method of analysis does not allow us to effectively study the dissociation kinetics of the dimer interaction.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Time course for dimer dissociation measured by size exclusion chromatography. Starting at ~25 µM, the dimer (rA4-C321S) was dissociated by dilution with buffer to 2, 0.75, or 0.35 µM. At different times after dilution, aliquots were taken and analyzed on a Superose 12 gel filtration column. All reactions were performed at 25 °C in 20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4. The monomeric species was detected by peak area of the elution profiles as described under "Experimental Procedures." The time scale does not reflect the true time post-dilution, and it was estimated that 100 s had elapsed before the column separation was initiated. The 100 s can be accounted for by sample dilution and mixing, sample application to the FPLC system, and injection onto the column. The data were fit by linear regression analysis.

Dimer Dissociation (rA4-C321S) as a Function of pH-- To analyze the dimer interaction, size exclusion chromatography at various concentrations of rA4-C321S was used to determine KD as a function of pH in a range between 6.0 and 9.0. A composite of the dissociation curves is represented in Fig. 5. The results are presented in Table I. The tightest interaction (KD ~ 229 nM) for the dimer was seen in the acidic pH range tested (6.0-7.4). From pH 6.0 (KD = 283 ± 32 nM, Delta G = 8.9 kcal/mol) to pH 7.4 (KD = 229 ± 26 nM, Delta G = 9.1 kcal/mol), little or no change (Delta KD = 54 nM, Delta Delta G = 0.2 kcal/mol) was observed for the binding interaction. In contrast, a marked change was observed when comparing pH 7.4 with pH 8.0 (KD = 229 ± 26 nM and Delta G = 9.1 kcal/mol versus KD = 614 ± 146 nM and Delta G = 8.5 kcal/mol). An ~2.7-fold increase in KD was observed, followed by a further 1.5-fold increase in KD at pH 9.0 (KD = 955 ± 122 nM, Delta G = 8.2 kcal/mol). Conclusively, an increase in pH causes a general destabilization of the rA4-C321S dimer interaction, reflected in an overall ~4.0-fold increase in KD (Delta Delta G = 0.8 kcal/mol) from pH 6.0 to 9.0. The destabilization trend observed as a function of pH provides evidence for a charge interaction at the dimer interface that aids in mediating dimer formation. A marked shift in binding affinity between pH 7.4 and 8.0 suggests the involvement of amino acid residue(s) with a pKa of ~8.0.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Composite of dissociation curves illustrating pH effects on dimer dissociation. Plots of percent dimer versus total C321S protein concentration were used to determine dimer dissociation constants (KD) at a range of pH values from 6.0 to 9.0. Total [C321S] represents the concentration of dimer that would be present if the protein were all dimer. Percent dimer is the percentage of protein that is actually dimer at various C321S concentrations.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of pH on dimer dissociation
Shown is the effect of pH on dimer dissociation represented in terms of KDM) and Gibbs free energy (Delta G, kcal/mol). The KD values were determined from plots of percent dimer versus [C321S] utilizing Kaleidagraph software and were corrected for 6.5-fold dilution of samples on the column as described under "Experimental Procedures." The Gibbs free energy of dissociation was calculated using the following equation: Delta G = -RT ln KD, where R is the gas constant (1.987 cal × mol-1 × K-1), T is the absolute temperature (298 K), and KD is the dimer dissociation constant experimentally determined.

Chromatography was also attempted for pH values below 6.0 and above 10.0 that are outside the range shown in Table II. The resultant chromatograms revealed evidence of peak broadening and inconsistencies in peak elution times. Therefore, it was not possible to interpret the results. However, these results suggest that the A4 domain (rA4-C321S) may be somewhat conformationally unstable in pH conditions below 6.0 and above 10.0. These results suggest three possibilities: global structural changes in the protein and/or changes in the rate of dissociation or interaction with the column material.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of salt on dimer dissociation
Shown is the effect of salt on dimer dissociation represented in terms of KDM) and Gibbs free energy (Delta G, kcal/mol). The KD values were determined from plots of percent dimer versus [C321S] utilizing Kaleidagraph software and were corrected for 6.5-fold dilution of samples on the column as described under "Experimental Procedures." The Gibbs free energy of dissociation was calculated using the following equation: Delta G = -RT ln KD, where R is the gas constant (1.987 cal × mol-1 × K-1), T is the absolute temperature (298 K), and KD is the dimer dissociation constant experimentally determined.

Dimer Dissociation (rA4-C321S) as a Function of Salt Concentration-- To analyze the dimer interaction, size exclusion chromatography at various concentrations of rA4-C321S was used to determine dissociation constants as a function of salt concentration between 0.025 and 2.0 M. A composite of the dissociation curves is represented in Fig. 6. The results are presented in the Table II. Salt concentrations of 0.025 and 0.05 M exhibited the tightest binding interactions, with KD values equal to ~163 nM (Delta G = 9.3 kcal/mol). At 0.1 M NaCl, KD = 229 ± 26 nM and Delta G = 9.1 kcal/mol were observed. A 15-fold increase in salt concentration (1.5 M NaCl) resulted in an ~2.9-fold decrease in binding affinity (KD = 662 ± 169 nM, Delta G = 8.4 kcal/mol). A salt concentration of 1.0 M NaCl (KD = 255 ± 66 nM, Delta G = 9.0 kcal/mol) did not reflect the overall trend and may be indicative of an aberrant observation. In general, an increase in salt concentration can cause a destabilization of the dimer interaction, as demonstrated by the ~4-fold decrease in binding affinity as the NaCl concentration was increased from 0.025 to 2.0 M. The results obtained while examining the effects of salt on the dimer interaction are consistent with the notion that electrostatic interactions contribute to FXI rA4 domain dimerization. Salt concentrations tested below 25 mM produced aberrant results, i.e. an increase in retention times for both the dimeric and monomeric species. These findings indicate that protein is being retarded by the column material as a result of nonspecific interactions with the column matrix or global changes in conformation.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Composite of dissociation curves illustrating salt effects on dimer dissociation. Plots of percent dimer versus total C321S protein concentration were used to determine dimer dissociation constants (KD) at a range of salt concentrations from 0.025 to 2.0 M. Total [C321S] represents the concentration of dimer that would be present if the protein were all dimer. Percent dimer is the percentage of protein that is actually dimer at various C321S concentrations.

Bis-ANS Titration-- We conducted studies to assess the role of hydrophobic interactions in A4 dimer formation. The apolar probe bis-ANS was used to titrate the A4 domain while monitoring extrinsic probe fluorescence. Upon binding to a hydrophobic moiety or hydrophobic cluster on the surface of a protein, one observes a severalfold increase in bis-ANS fluorescence intensity (29). In comparison with bis-ANS emission maximum (553 nm) when the dye is unbound and in aqueous medium, one also observes a blue-shifted emission maximum upon binding of the dye to a hydrophobic moiety (30). The extent of both the fluorescence intensity increase and the shift in emission maxima is strictly dependent upon the environment of the dye-binding site (31). An increase in the bis-ANS fluorescence and a shift in the emission maximum from 533 to 497 nm were observed upon addition of saturating levels of bis-ANS (10 µM) to rA4-C321S (0.5 µM) (data not shown). When higher concentrations of dye were added, we observed no further shift in the emission maximum, which is suggestive of a single dye-binding site (32). As a control, the fluorescence intensity of 10 µM bis-ANS in buffer (in the absence of protein) was negligible compared with the fluorescence of dye in the presence of protein (data not shown). We compared the wild-type rA4 domain (0.5 µM) and the rA4-C321S domain (0.5 µM) in the presence of increasing amounts of bis-ANS and noted the change in relative bis-ANS fluorescence (Fig. 7). Binding of the probe to the mutant rA4-C321S domain showed saturable binding, along with a marked increase in probe fluorescence, as evidenced by a plot that was hyperbolic in character (Fig. 7). The hyperbolic nature of the curve is indicative of a single dye-binding site with a KD equal to ~2 µM. In contrast, the covalently linked, fully dimeric wild-type rA4 domain showed little or no significant ability to bind the apolar probe, as evidenced by the absence of a detectable increase in relative bis-ANS fluorescence. These results suggest the absence of hydrophobic sites on the surface of the covalently linked rA4 domain. To test the specificity of the dye-binding site on the rA4-C321S domain, a denatured rA4-C321S domain incubated in 6 M guanidine hydrochloride was titrated with bis-ANS. The results demonstrated a small amount of nonspecific binding of the dye, as evidenced by the linear plot shown in Fig. 7. The dye-binding site exposed on the surface of the partially dissociated native rA4-C321S domain can be disrupted by exposure of the protein to denaturant. These findings suggest that the hydrophobic site exposed only in the presence of the dissociated dimer must contain some conformational specificity.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   Titration of the A4 domain with bis-ANS. Shown are the results of titration of the A4 domain at different concentrations of the apolar probe bis-ANS. The increase in bis-ANS fluorescence (arbitrary units) was measured at a fixed emission wavelength of 497 nm. The C321S mutant under both denaturing (guanidine hydrochloride (GuHCl)) and nondenaturing conditions and the covalently linked wild-type (WT) A4 domains were at concentrations of 0.5 µM. The covalently linked dimeric wild-type A4 domain and the denatured C321S mutant showed no significant change in fluorescence compared with the freely dissociable C321S mutant. We were able to detect a change in the exposure of hydrophobic patch(es) due to increased bis-ANS binding as result of A4 dimer (C321S) dissociation.

In conclusion, these results give clear indication that a saturable hydrophobic site(s) is exposed only upon dimer dissociation and that this site(s) can be disrupted by denaturation of the protein. A hydrophobic patch present only on the monomeric subunit gives credence to the argument that a hydrophobic component exists at the homodimer interface, which may be in part responsible for mediating A4 dimer formation.

Kinetics of rA4-C321S Dissociation-- The change in the fluorescence of bis-ANS upon binding to the dissociated rA4-C321S domain was useful for monitoring the kinetics of dissociation (Fig. 8). Concentrated stock solutions (25-100 µM) of both the rA4-C321S and rA4 domains were diluted to a final concentration of 0.5 µM in the presence of 10 µM bis-ANS and monitored for increases in bis-ANS fluorescence. We observed an increase in bis-ANS fluorescence for rA4-C321S, which follows a single exponential reaction with a dissociation rate constant (koff) of 4.3 × 103 s-1 for the dissociation of dimer to monomer (Fig. 8). Utilizing the previously determined KD of 229 ± 26 nM (size exclusion chromatography), we were able to calculate an association rate constant (kon) for the conversion of monomer to dimer of 1.9 × 104 M-1 s-1 (see "Experimental Procedures"). The determination of the kinetic parameters associated with the rA4 domain monomer-dimer equilibrium provides a detailed look at the kinetic mechanism behind the dimer interaction of the rA4 domain as well as the noncovalent interaction of FXI as a whole. It is of critical importance to point out that this assay is based on the assumption that bis-ANS binds to the dissociated monomer at a much faster rate compared with the rate of dissociation of the dimer. We can make this statement since the rate of encounter of a small molecule with a large molecule for a diffusion-controlled reaction gives a second-order rate constant in the range of 109-1011 M-1 s-1 (33). If we hypothesize that the true rate of association for the apolar probe were altered by 3 orders magnitude (106 M-1 s-1), accounting for changes in protein conformation upon association of the probe with the protein, the rate of binding of the probe (104 s-1 at 10 µM bis-ANS) to the protein would still be much faster compared with our observed rate for dimer dissociation of 4.3 × 10-3 s-1. Therefore, in this experiment, we are observing the dissociation of the rA4-C321S dimer and not the binding of bis-ANS to the monomer. Moreover, the covalently linked wild-type protein (rA4) does not bind the apolar probe, demonstrating the specificity of the probe for the dimer interface. These observations are in accordance with the bis-ANS titration experiments, in which we observed no increase in bis-ANS fluorescence in the presence of the wild-type rA4 domain.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Kinetics of rA4-C321S dissociation as monitored by the binding of bis-ANS. rA4-C321S and the rA4 domain were diluted to 0.5 µM in the presence of 10 µM bis-ANS. The kinetics of dissociation was monitored by following the increase in bis-ANS due to the binding of the probe to the dissociated monomers (rA4-C321S). The covalently linked dimeric wild-type rA4 domain showed no significant change in fluorescence compared with the freely dissociable rA4-C321S mutant. The increase in bis-ANS fluorescence was measured at a fixed wavelength of 497 nm (excitation at 385 nm). The curve was fit according to a first-order reaction.

The findings of both the fluorescence assay (kinetics of dissociation) and the gel filtration assay are mutually consistent. Based on the experimentally determined rate of dissociation (koff = 4.3 × 10-3 s-1), we calculated a half-life (t1/2 for the dissociation reaction of 160 s. In the time scale of the gel filtration experiment in which the majority of the determinations were made 10 min (3.7 half-lives) after dilution, we would expect at least 92% of the equilibrium to have been achieved (Fig. 4). This provides an explanation as to why in this experiment we observed no change in monomer concentration over time and also provides a justification for correcting values of KD(app) to account for the 6.5-fold dilution of protein samples during the gel filtration dimerization assay (see "Experimental Procedures").


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results presented in this paper demonstrate the feasibility of studying the noncovalent dimer interaction of FXI by use of a recombinantly generated A4 domain. Herein we report the KD (~230 nM) and the Gibbs free energy of dissociation (Delta G ~ 9 kcal/mol) for the rA4-C321S noncovalent mutant under physiologic conditions, as determined by size exclusion chromatography. We also report a koff of 4.3 × 10-3 s-1 and a calculated kon of 1.9 × 104 M-1 s-1 using fluorescence spectroscopy.

The FXI rA4 domain and the rA4-C321S mutant have been purified and characterized, including their capacity to form both covalent and noncovalent dimers, DNA sequencing of the recombinant DNA, mass spectroscopic analysis of the protein product, and N-terminal sequence analysis. Considering the enormous number of disulfide bond combinations (135,135) that are theoretically possible in a protein like the rA4 domain with a total of seven cysteines (25, 26), we took great pains in characterizing the rA4 domains. The single most important line of evidence that these proteins are conformationally intact is the fact that they maintain their capacity to form dimers. Moreover, the rA4 domain exists as a single species upon reverse-phase HPLC, mass spectroscopy, and gel filtration, supporting the conclusion that the protein is homogeneous and conformationally intact (34). We also tested our proteins for their susceptibility to protease cleavage. Both trypsin and endoproteinase Lys-C were unable to cleave the rA4 domains, as monitored by SDS-PAGE (data not shown). While elucidating the disulfide bond arrangement in FXI, McMullen et al. (9) similarly observed resistance to trypsin proteolysis for an isolated fragment containing the entire A4 domain (His267-Met358). In the native conformation, a majority of proteins possess some protease resistance, and proteolysis typically takes place in regions that are typically exposed or disordered (35). Therefore, one might expect that if the rA4 domain were folded incorrectly, cleavage by the previously mentioned proteases would occur more readily. We conclude that all of the rA4 domain polypeptides exist in native conformation.

Molecular sieve chromatography or size exclusion chromatography has been well described in the literature and has become a valuable tool for determining equilibrium constants for reversibly associating systems (28, 36, 37). Values obtained by this technique have been shown to be reliably comparable to sedimentation equilibrium and fluorescence depolarization assays, among other techniques designed to scrutinize multimer equilibria (22, 27). The results presented in Figs. 3-6 provide evidence for a process in which a mixture of both dimeric and monomeric rA4 domains is unaffected by the chromatography process and exists in a slowly exchanging equilibrium (28). In a slowly exchanging system like ours, the separation process (column chromatography) is faster than the reversible exchange of dimer and monomer. This explains why we observed two well resolved, highly symmetrical peaks in our study (28, 37).

We examined the influence of pH on the dissociation equilibrium using the freely dissociable mutant (rA4-C321S) and observed an increase in KD at the more alkaline pH values tested (Table I). Although the pH effect could be due to deprotonation of an ionizable group (or groups) on the protein resulting in a structural distortion of the protein, we observed a high degree of peak uniformity and consistency of retention times, suggesting that the proteins are behaving uniformly both in respect to their Stokes radii and lack of interaction with the column matrix (28). We can therefore theorize that the pH effects are attributed to a deprotonation of a critical amino acid side chain involved in the dimer interaction. The most significant changes in KD occur in the pH range between 7.4 to 8.0 (~2.7-fold increase in KD), suggesting deprotonation of a side chain with a pKa value of ~7.4-8.0. There are only two possible candidates: cysteine (pKa = 8.5) and the N-terminal amino group (pKa = 8.0) (38, 39). Since all cysteine residues within the A4 domain in both the full-length FXI molecule (9) and our own protein constructs (see "Results") are engaged in disulfide linkages, there are no free sulfhydryl groups to mediate dimer formation. The N-terminal amino group of the A4 domain (Phe271) is engaged within FXI in a peptide bond with its neighboring residue (Val270). Moreover, both the FXI rA4 and rA4-C321S domains are capable of forming dimers with and without the histidine tag present (data not shown). Furthermore, if the N terminus were located at the dimer interface, bovine Xa probably would not have steric access to the cleavage site, and this would present a problem for removal of the 6-His tag. Therefore, it is highly unlikely that the N terminus of the rA4 subunit plays a role in the dimer interaction. It is difficult to predict accurately the ionization behavior of any one group without additional information. However, we can conclude from our analysis that an increase in pH affects the ability of the A4 domain to associate, suggesting the possibility that deprotonation of an amino acid side chain with a perturbed pKa due to its microenvironment directly weakens the monomer interactions. The obvious implication from this analysis is that an electrostatic component mediates dimer formation; whether we are observing a specific side chain contribution or global charge repulsion remains to be seen. In any event, it is this type of information that will provide the basic knowledge about the oligomerization of proteins within a cell and the rationale for future experimentation designed to answer questions about the nature of the FXI dimer interface.

Electrostatic complementarity has been proposed to play a significant role in the formation of a large number of protein complexes (43). For example, homodimers of MyoD are subsequently destabilized by increasing salt, which, in turn, confirmed an electrostatic contribution to subunit interactions first suggested by crystallographic studies (44, 45). The study of cytochrome P-450 and P-450 reductase has revealed an interaction that is also held together by complementary charged residues (46-48). Electrostatic interactions play an important role in the dimerization of FXI mediated by the A4 domain. The shift in equilibrium toward monomer at the high concentrations of salt (Table II) is thought to be a result of charge shielding by the addition of ions and a reduction in the productive charge interactions at the interface (49, 50). When small diffusible ions such as Na+ and Cl- are present in an aqueous environment, the ions tend to concentrate in the vicinity of charges that are opposite in sign (positive versus negative) (51). Therefore, the increase in salt concentration would gradually neutralize the charge interactions by subsequently weakening the resultant protein-protein interaction at the A4 dimer interface. Under conditions of high salt, water molecules tend to be excluded at protein interfaces (51, 52), intensifying an existing hydrophobic interaction resulting in lower KD values. Since we did not observe a large change in KD or Delta G due to increasing salt concentrations, we can speculate that the increase in salt may intensify an existing hydrophobic interaction at the dimer interface compensating for the destabilizing effect seen due to shielding of charges at the interface.

The specificity of the bis-ANS probe for hydrophobic moieties on the surface of proteins (53) has led to many studies, including the characterization of protein interface contacts between subunits found in coagulation cofactor VIII (32). The probe permitted the identification of a surface-exposed hydrophobic site on dissociated rA4-C321S as well as the absence of hydrophobic sites on the covalently linked rA4 domain. The presence of a site only on the dissociated subunits is suggestive of its involvement in homodimer formation. These results provide clear evidence of a hydrophobic component present at the A4 dimer interface and demonstrate that the bis-ANS probe binds only to a single affinity dye-binding site. These findings are also in agreement with the salt-dependent changes seen in binding affinity, which suggest that the hydrophobic component can compensate for the charge destabilization caused by increasing salt concentrations.

Our study has clear implications for the assembly mechanism of FXI as well as for the study of oligomeric proteins in general. Our results are consistent with published studies of homodimer interfaces that indicate that the overall proportions of nonpolar interactions (van der Waals and hydrophobic) and polar interactions (hydrogen bonds) tend to vary greatly from one oligomer interface to another (54). The majority of the interfaces surveyed contained a mixture of small hydrophobic patches, polar interactions, and water molecules scattered over the entire interface (55).

This study provides an initial characterization of the interaction between the two monomeric subunits of FXI and provides seminal information that will guide future investigations of platelet-associated coagulation reactions and function of FXI (56). Since the dimeric nature of FXI may be critical for its ability to function properly on the platelet surface (16, 20, 21), it is important to understand the mechanism of FXI dimerization. A future goal is to compare full-length FXI with the rA4 proteins to determine whether all of the binding information resides within the A4 domain. It will be interesting to compare the rA4 domain with the full-length FXI C321S mutant to determine whether another region of the FXI molecule could harbor additional binding energy. Such studies would be facilitated by the development of dimerization assays such as fluorescence polarization (44, 57) and isothermal titration calorimetry (58), solution-based methods that provide a true equilibrium measurement that does not require separation of free and bound species. Such studies, together with structural information from NMR and x-ray crystallography combined with site-directed mutational analysis, will allow us to examine individual amino acid contributions made at the dimer interface.


    ACKNOWLEDGEMENTS

We are grateful to Drs. Charles T. Grubmeyer and Parkson Lee-Gau Chong for valuable suggestions concerning experimental design and interpretation and to Patricia Pileggi for assistance in manuscript preparation.


    FOOTNOTES

* This study was supported by National Institutes of Health Research Grants HL46213, HL56914, and HL64943 (previously HL56153) (to P. N. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad St., Philadelphia, PA 19140. Tel.: 215-707-4375; Fax: 215-707-3005; E-mail: pnw@astro.ocis.temple.edu.

Published, JBC Papers in Press, November 22, 2000, DOI 10.1074/jbc.M010340200


    ABBREVIATIONS

The abbreviations used are: FXI, factor XI; FXIa, activated factor XI; A4, Apple 4; rA4, recombinant Apple 4; PAGE, polyacrylamide gel electrophoresis; IPTG, isopropyl-beta -D-thiogalactopyranoside; CAPS, 3-(cyclohexylamino)propanesulfonic acid; MES, 2-(N-morpholino)ethanesulfonic acid; NTA, nitrilotriacetic acid; PCR, polymerase chain reaction; bis-ANS, 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid dipotassium salt; HPLC, high performance liquid chromatography; FPLC, fast protein liquid chromatography.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Davie, E. W., Fujikawa, K., and Kisiel, W. (1991) Biochemistry 30, 10363-10370[Medline] [Order article via Infotrieve]
2. Saito, H., and Goldsmith, G. H., Jr. (1977) Blood 50, 377-385[Abstract]
3. Thompson, R. E., Mandle, R., Jr., and Kaplan, A. P. (1977) J. Clin. Invest. 60, 1376-1380[Medline] [Order article via Infotrieve]
4. Kurachi, K., and Davie, E. W. (1977) Biochemistry 16, 5831-5839[Medline] [Order article via Infotrieve]
5. Naito, K., and Fujikawa, K. (1991) J. Biol. Chem. 266, 7353-7358[Abstract/Free Full Text]
6. Fujikawa, K., Chung, D. W., Hendrickson, L. E., and Davie, E. W. (1986) Biochemistry 25, 2417-2424[Medline] [Order article via Infotrieve]
7. Fujikawa, K., Legaz, M. E., Kato, H., and Davie, E. W. (1974) Biochemistry 13, 4508-4516[Medline] [Order article via Infotrieve]
8. Asakai, R., Davie, E. W., and Chung, D. W. (1987) Biochemistry 26, 7221-7228[Medline] [Order article via Infotrieve]
9. McMullen, B. A., Fujikawa, K., and Davie, E. W. (1991) Biochemistry 30, 2056-2060[Medline] [Order article via Infotrieve]
10. Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1992) J. Biol. Chem. 267, 4247-4252[Abstract/Free Full Text]
11. Baglia, F. A., and Walsh, P. N. (1996) J. Biol. Chem. 271, 3652-3658[Abstract/Free Full Text]
12. Baglia, F. A., and Walsh, P. N. (1998) Biochemistry 37, 2271-2281[CrossRef][Medline] [Order article via Infotrieve]
13. Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1991) J. Biol. Chem. 266, 24190-24197[Abstract/Free Full Text]
14. Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1995) J. Biol. Chem. 270, 6734-6740[Abstract/Free Full Text]
15. Ho, D. H., Badellino, K., Baglia, F. A., and Walsh, P. N. (1998) J. Biol. Chem. 273, 16382-16390[Abstract/Free Full Text]
16. Ho, D. H., Baglia, F. A., and Walsh, P. N. (2000) Biochemistry 59, 316-323[CrossRef]
17. Sun, Y., and Gailani, D. (1996) J. Biol. Chem. 271, 29023-29028[Abstract/Free Full Text]
18. Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1993) J. Biol. Chem. 268, 3838-3844[Abstract/Free Full Text]
19. Meijers, J. C., Mulvihill, E. R., Davie, E. W., and Chung, D. W. (1992) Biochemistry 31, 4680-4684[Medline] [Order article via Infotrieve]
20. Gailani, D., Sun, M.-F., Ho, D., Zhao, M., Cheng, Q., and Walsh, P. N. (1999) Blood 94, 621a (abstr.)
21. Wolberg, A. S., Morris, D. P., and Stafford, D. W. (1997) Biochemistry 36, 4074-4079[CrossRef][Medline] [Order article via Infotrieve]
22. Manning, L. R., Jenkins, W. T., Hess, J. R., Vandegriff, K., Winslow, R. M., and Manning, J. M. (1996) Protein Sci. 5, 775-781[Abstract/Free Full Text]
23. Picard, V., Ersdal-Badju, E., Lu, A., and Bock, S. C. (1994) Nucleic Acids Res. 22, 2587-2591[Abstract]
24. Saxena, V. P., and Wetlaufer, D. B. (1970) Biochemistry 9, 5015-5023[Medline] [Order article via Infotrieve]
25. Jaehicke, R., and Rudolph, R. (1989) in Protein Structure: A Practical Approach (Creighton, T. E., ed) , pp. 191-222, IRL Press Ltd., Oxford, England
26. Creighton, T. E. (ed) (1992) Protein Folding , W. H. Freeman & Co., New York
27. Gallagher, C. N., and Huber, R. E. (1997) Biochemistry 36, 1281-1286[CrossRef][Medline] [Order article via Infotrieve]
28. Ackers, G. K., and Thompson, T. E. (1965) Biochemistry 342-349
29. Ptitsyn, O. B. (1994) Protein Eng. 7, 593-596[Medline] [Order article via Infotrieve]
30. Shi, L., Palleros, D. R., and Fink, A. L. (1994) Biochemistry 33, 7536-7546[Medline] [Order article via Infotrieve]
31. Stryer, L. (1965) J. Mol. Biol. 13, 482-495[Medline] [Order article via Infotrieve]
32. Sudhakar, K., and Fay, P. J. (1996) J. Biol. Chem. 271, 23015-23021[Abstract/Free Full Text]
33. Fersht, A. (1999) Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding , pp. 147-154, W. H. Freeman & Co., New York
34. Wu, J., and Watson, J. T. (1997) Protein Sci. 6, 391-398[Abstract/Free Full Text]
35. Carrey, E. A. (1989) in Protein Structure: A Practical Approach (Creighton, T. E., ed) , pp. 117-143, IRL Press, Oxford, England
36. Zimmerman, J. K., and Ackers, G. K. (1971) J. Biol. Chem. 246, 7289-7292[Abstract/Free Full Text]
37. Uversky, V. N. (1993) Biochemistry 32, 13288-13298[Medline] [Order article via Infotrieve]
38. Stryer, L. (1988) Biochemistry , pp. 16-21, W. H. Freeman & Co., New York
39. Creighton, T. E. (1993) Proteins: Structures and Molecular Properties , 2nd Ed. , p. 6, W. H. Freeman & Co., New York
40. Deleted in proof
41. Deleted in proof
42. Deleted in proof
43. McCoy, A. J., Chandana Epa, V., and Colman, P. M. (1997) J. Mol. Biol. 268, 570-584[CrossRef][Medline] [Order article via Infotrieve]
44. Maleki, S. J., Royer, C. A., and Hurlburt, B. K. (1997) Biochemistry 36, 6762-6767[CrossRef][Medline] [Order article via Infotrieve]
45. Ma, P. C., Rould, M. A., Weintraub, H., and Pabo, C. O. (1994) Cell 77, 451-459[Medline] [Order article via Infotrieve]
46. Bernhardt, R., Kraft, R., Otto, A., and Ruckpaul, K. (1988) Biomed. Biochim. Acta 47, 581-592[Medline] [Order article via Infotrieve]
47. Nadler, S. G., and Strobel, H. W. (1988) Arch Biochem. Biophys. 261, 418-429[Medline] [Order article via Infotrieve]
48. Shimizu, T., Tateishi, T., Hatano, M., and Fujii-Kuriyama, Y. (1991) J. Biol. Chem. 266, 3372-3375[Abstract/Free Full Text]
49. Moulis, J. M., and Davasse, V. (1995) Biochemistry 34, 16781-16788[Medline] [Order article via Infotrieve]
50. Voznesensky, A. I., and Schenkman, J. B. (1994) J. Biol. Chem. 269, 15724-15731[Abstract/Free Full Text]
51. Arakawa, T., and Timasheff, S. N. (1985) Methods Enzymol. 114, 49-77[Medline] [Order article via Infotrieve]
52. Scopes, R. K. (1994) in Protein Purification: Principles and Practice (Cantor, C. R., ed), Third Ed. , pp. 71-85, Springer-Verlag New York Inc., New York
53. Semisotnov, G. V., Rodionova, N. A., Razgulyaev, O. I., Uversky, V. N., Gripas, A. F., and Gilmanshin, R. I. (1991) Biopolymers 31, 119-128[Medline] [Order article via Infotrieve]
54. Janin, J., Miller, S., and Chothia, C. (1988) J. Mol. Biol. 204, 155-164[Medline] [Order article via Infotrieve]
55. Larsen, T. A., Olson, A. J., and Goodsell, D. S. (1998) Structure 6, 421-427[Abstract]
56. Walsh, P. N. (1981) Fed. Proc. 40, 2086-2091[Medline] [Order article via Infotrieve]
57. Lundblad, J. R., Laurance, M., and Goodman, R. H. (1996) Mol. Endocrinol. 10, 607-612[Abstract]
58. Aoki, K., Taguchi, H., Shindo, Y., Yoshida, M., Ogasahara, K., Yutani, K., and Tanaka, N. (1997) J. Biol. Chem. 272, 32158-32162[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
276/9/6429    most recent
M010340200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Dorfman, R.
Articles by Walsh, P. N.
Articles citing this Article
PubMed
PubMed Citation
Articles by Dorfman, R.
Articles by Walsh, P. N.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.